Prospective Cohort Study and Emulated Target Trial to Estimate the Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany (SEMVAc/TEMVAc)

First published 15/12/2022

Last updated 20/09/2024

EU PAS number:

EUPAS50093

Study

Finalised

Documents

Study protocol

Initial protocol

20221202_SEMVAc_V1.3 final_shared version

English (534.65 KB - PDF)View document

Study results

Study report

SEMVAc and TEMVAc_Extended Study Report.pdf

English (4.69 MB - PDF)View document

Other information

Study, other information

Annex 2_Supplementary Material_SEMVAc and TEMVAc extended study report.pdf

English (1.69 MB - PDF)View document

Secondary tabs